SPRINT

收缩压干预试验（SPRINT）是一项2组、多中心、随机临床试验，旨在测试旨在降低收缩压（SBP）至低于目前推荐目标的治疗方案是否会降低心血管疾病（CVD）风险。约9250名收缩压大于或等于130毫米汞柱且至少有一个额外的心血管疾病危险因素的参与者将在5个临床中心网络（ccn）的大约80个诊所招募，为期2年，并将随访4-6年。大约4300名参与者将患有慢性肾脏疾病（CKD），大约3250名参与者将年龄在75岁或以上。主要结局是首次发生心肌梗死（MI）、急性冠状动脉综合征（ACS）、中风、心力衰竭（HF）或心血管疾病死亡。次要结局包括全因死亡率、肾功能下降或终末期肾病（ESRD）、痴呆、认知功能下降和小血管缺血性疾病。

The Systolic Blood Pressure Intervention Trial (SPRINT) is a 2-arm, multicenter, randomized clinical trial designed to test whether a treatment program aimed at reducing systolic blood pressure (SBP) to a lower goal than currently recommended will reduce cardiovascular disease (CVD) risk. About 9250 participants with SBP greater than or equal to 130 mm Hg and at least one additional CVD risk factor will be recruited at approximately 80 clinics within 5 clinical center networks (CCNs) over a 2-year period, and will be followed for 4-6 years. Approximately 4300 participants will have chronic kidney disease (CKD), and about 3250 will be aged 75 or older. The primary outcome is the first occurrence of a myocardial infarction (MI), acute coronary syndrome (ACS), stroke, heart failure (HF), or CVD death. Secondary outcomes include all-cause mortality, decline in renal function or development of end stage renal disease (ESRD), dementia, decline in cognitive function, and small vessel cerebral ischemic disease.